M. Venditti, M. Falcone, S. Corrao, G. Licata and P. Serra, “Outcomes of Patients Hospitalized with Community-Acquired, Health Care-Associated, and Hospital- Acquired Pneumonia,” Annals of Internal Medicine, Vol. 150, No. 1, 2009, pp. 19-26.

has been cited by the following article:

• TITLE: Telavancin in Experimental Murine Pneumococcal Pneumonia

  AUTHORS: Suzannah M. Schmidt, Melissa J. Karau, Jayawant N. Mandrekar, James M. Steckelberg, Robin Patel

  KEYWORDS: Telavancin; Murine; Pneumonia

  JOURNAL NAME: Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol.1 No.2, July 23, 2012

  ABSTRACT: We determined whether telavancin is as active in experimental immunocompetent murine pneumococcal pneumonia as is vancomycin or ceftriaxone. Experimental murine pneumonia was established by intratracheal administration of Streptococcus pneumoniae. Four groups of animals were studied, untreated and treated with vancomycin (110 mg/kg, bid, SQ), telavancin (40 mg/kg, bid, SQ), or ceftriaxone (50 mg/kg, bid, SQ) for 2 days. The untreated animals had a mean of 6.54 ± 0.82 log10 cfu/g lung. The vancomycin-, telavancin-, and ceftriaxone-treated animals had means of 2.01 ± 0.02, 2.00 ± 0.00, and 2.00 ± 0.01 log10 cfu/g lung, respectively (p-values